Business & Finance
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
21 October 2025 - Cumberland Pharmaceuticals Inc (Nasdaq:CPIX), a US-based specialty pharmaceutical company, announced on Monday that it has entered into strategic arrangements with RedHill Biopharma ...
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
13 October 2025 - IP Group plc (LSE: IPO), an investor in breakthrough science and innovation companies, on Monday outlined potential future royalty income linked to obesity drug candidates developed ...
AstraZeneca strikes landmark drug pricing deal with US Government
13 October 2025 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN (STO: AZN) (Nasdaq: AZN) announced on Monday that it has reached a historic agreement with the administration of President Donald ...
Aptamer Group wins GBP360,000 contract with global pharmaceutical company for radiopharmaceutical development
8 October 2025 - Aptamer Group plc (AIM: APTA), a developer of next-generation synthetic binders, revealed on Wednesday that it has secured a GBP360,000 development contract with a top three global ph...
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
8 October 2025 - Fusion Antibodies plc (AIM: FAB), a Belfast-based specialist in pre-clinical antibody discovery and engineering, announced on Wednesday that it has been awarded a new multi-target Int...
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
29 September 2025 - Danish biotechnology company Genmab A/S (CPH:GMAB) announced on Monday that it has agreed to acquire clinical-stage oncology company Merus N.V. (Nasdaq:MRUS) in an all-cash transac...